Hormone may help fight obesity and reduce cholesterol
2013-09-03
(Press-News.org) Research has shown that giving obese rodents a recently identified circulating protein called fibroblast growth factor 21 (FGF21) helps improve their metabolism. Now investigators reporting in the Cell Press journal Cell Metabolism reveal that a variant of FGF21 has similar effects in obese people with type 2 diabetes.
"Our findings suggest that FGF21 has the ability to favorably affect body weight and to partially normalize abnormal lipid levels in patients with diabetes. These are substantial issues and unmet medical needs for patients with obesity and type 2 diabetes," says senior author Dr. David Moller, vice president of endocrine and cardiovascular research at Eli Lilly and Company.
Lilly scientists initially identified FGF21 as a novel target for its potential in treating metabolic disorders. Dr. Moller and his colleagues studied the effects of LY2405319 (LY), a variant of FGF21, in a randomized, placebo-controlled, double-blind proof-of-concept trial in 46 patients with obesity and type 2 diabetes. LY treatment led to decreases in LDL cholesterol and triglycerides, increases in HDL cholesterol, and decreases in atherosclerosis-causing lipoproteins.
LY also reduced body weight and fasting insulin, and it increased adiponectin, a hormone produced by fat cells that may augment insulin's effects. While there was only a slight lowering of blood glucose levels in patients treated with LY, the study's results indicate that FGF21 is active in humans and suggest that FGF21-based therapies may be effective for treating metabolic disorders.
"We are encouraged by the potential of FGF21 to produce multiple metabolic effects in people with diabetes and are evaluating further concepts for FGF21-based therapies," says Dr. Moller. He notes that most people with diabetes have other risk factors related to metabolic syndrome, including glucose intolerance, abdominal obesity, elevated triglycerides, low HDL cholesterol levels, and hypertension. No currently available treatment is able to address more than one of these conditions. "Thus, combination therapy is usually prescribed and often leads to tolerability issues, poor patient compliance, and suboptimal outcomes, all of which provide an incentive to continue the search for new therapeutic approaches," Dr. Moller explains.
###
Cell Metabolism, Gaich et al.: "The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes."
END
ELSE PRESS RELEASES FROM THIS DATE:
2013-09-03
An antihistamine discovered in the 1950s to treat itching may also prevent seizures in an intractable form of childhood epilepsy, according to researchers at UC San Francisco who tested it in zebrafish bred to mimic the disease.
The researchers said their unexpected discovery offers a glimmer of hope for families of children with Dravet Syndrome, a rare genetic disorder that manifests in early childhood with disabling, lifelong consequences. These include dozens, if not hundreds, of daily seizures, as well as profound cognitive and social deficits.
“It is very ...
2013-09-03
RIVERSIDE, Calif. (http://www.ucr.edu) — A team of University of California, Riverside researchers have developed a novel transparent skull implant that literally provides a "window to the brain", which they hope will eventually open new treatment options for patients with life-threatening neurological disorders, such as brain cancer and traumatic brain injury.
The team's implant is made of the same ceramic material currently used in hip implants and dental crowns, yttria-stabilized zirconia (YSZ). However, the key difference is that their material has been processed ...
2013-09-03
Among scientists, the role of proteins called sirtuins in enhancing longevity has been hotly debated, driven by contradictory results from many different scientists. But new research at Washington University School of Medicine in St. Louis may settle the dispute.
Reporting Sept. 3 in Cell Metabolism, Shin-ichiro Imai, MD, PhD, and his colleagues have identified the mechanism by which a specific sirtuin protein called Sirt1 operates in the brain to bring about a significant delay in aging and an increase in longevity. Both have been associated with a low-calorie diet.
The ...
2013-09-03
Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013.
"Guidelines recommend blood pressure reduction in patients with hypertension with a treatment goal of 140 mm Hg for systolic and 90 mm Hg diastolic blood ...
2013-09-03
ANN ARBOR—When the tiny roundworm C. elegans reaches middle age—at about 2 weeks old—it can't quite move like it did in the bloom of youth. But rather than imposing an exercise regimen to rebuild the worm's body-wall muscles, researchers can bring the wriggle back by stimulating the animal's neurons. And, they say, pharmaceuticals might have a similar effect in mammals.
Scientists at the University of Michigan's Life Sciences Institute and Medical School have found that the loss of motor ability associated with aging begins in neurons and spreads to muscles, and that ...
2013-09-03
According to new research on epilepsy, zebrafish have certainly earned their stripes. Results of a study in Nature Communications suggest that zebrafish carrying a specific mutation may help researchers discover treatments for Dravet syndrome (DS), a severe form of pediatric epilepsy that results in drug-resistant seizures and developmental delays.
Scott C. Baraban, Ph.D., and his colleagues at the University of California, San Francisco (UCSF), carefully assessed whether the mutated zebrafish could serve as a model for DS, and then developed a new screening method ...
2013-09-03
A long-term study of children with a complex heart condition called hypertrophic cardiomyopathy (HCM) found that the risk of death or need for immediate listing for heart transplantation was greatest for those who developed this disease as infants with congestive heart failure and for children who also had selective inborn errors of metabolism, a group of rare genetic disorders in which one or more of the body's key metabolic processes are disrupted.
The findings will be published online Tuesday in The Lancet to coincide with a presentation at the European Society of ...
2013-09-03
Amsterdam, The Netherlands – Tuesday 3 September 2013: Being underweight increases the death risk of women with coronary artery disease (CAD) by 2-fold, according to research presented at the ESC Congress today by Dr Aziza Azimi from Denmark. The study suggests that underweight women with CAD should gain weight to reduce their risk of death.
Dr Azimi said: "The increasing prevalence of obesity is concerning because it is a major risk factor for cardiovascular disease, early death and other diseases like diabetes mellitus type 2, high blood pressure, and high cholesterol. ...
2013-09-03
Amsterdam, The Netherlands – Tuesday 3 September 2013: Infections cause a lower proportion of lead extractions than expected, according to preliminary results from the ELECTRa Registry presented at ESC Congress 2013 today by Dr Maria Grazia Bongiorni from Italy.
The European Lead Extraction ConTRolled (ELECTRa) Registry is the first large prospective, multicentre, European controlled registry of consecutive patients undergoing transvenous lead extraction (TLE) procedures in European real world practice. It is carried out by the European Heart Rhythm Association (EHRA) ...
2013-09-03
RIVERSIDE, Calif. — A team of researchers from the University of California, Riverside's Bourns College of Engineering have solved a problem that previously presented a serious hurdle for the use of graphene in electronic devices.
Scanning electron microscopy image of graphene device used in the study. The scale bar is one micrometer. The UCR logo next to it is implemented with etched graphene.
Graphene is a single-atom thick carbon crystal with unique properties beneficial for electronics including extremely high electron mobility and phonon thermal conductivity. However, ...
LAST 30 PRESS RELEASES:
[Press-News.org] Hormone may help fight obesity and reduce cholesterol
